Bob Whitehead

Happily Married. ARMY Veteran. Catholic. Proud Father. Love God, My Family, and This Great Nation.

[Susan G. Komen @SusanGKomen]

🧬 Sara Hurvitz, MD presents VIKTORIA-1 at #ASCO26: In HR+/HER2- PIK3CA-mutant breast cancer after CDK4/6i, gedatolisib + fulvestrant (with or without palbociclib) doubled progression-free survival vs standard of care (11.1 vs 5.6 months). 🎯 @ASCO

[Bob Whitehead @BobWhitehead12]

@thomas_garrard Great news

[The Real Mike Rowe @mikeroweworks]

If you’re tired of seeing my face in your newsfeed or on the TV, apologies in advance, because it’s about to get a lot worse. By the end of the year, you’re going to be absolutely sick of me, due to America’s ever widening skills gap, and our ongoing attempts to close it with a record number of work ethic scholarships from mikeroweWORKS, and therefor, a record number of invitations to apply.

The situation is serious. Skilled tradespeople are retiring much faster than they’re being replaced. For every 5 that leave the workforce, two come in. The math is not sustainable, and not a week goes by that I don’t hear from some industry leader wondering if I can help with their recruiting challenges. Every trade is in demand like never before. In fact, there’s been so much outreach from so many CEO’s and elected officials, that we’ve doubled the size of our scholarship fund, and extended the application period this year from six weeks to nine months.

Last year, we received 10X the number of applications we normally get, and this year, with the disruption of AI, I suspect the number will be even higher. These are AI-proof, six-figure jobs that don’t require college debt, but instead, training. Thus, I will be cluttering up the media landscape with an onslaught of invitations to apply for scholarships, (like the one attached,) and good-natured appeals to support our efforts with a modest (or immodest) donation.

Toward that end, I’m pleased to announce that the enrollment period is officially open. Funds are now available to help train the next generation of skilled workers. My goal this year is to award $10 million in scholarships, and you’re invited to apply today. Or, if the spirit moves you, to support our efforts with a donation of any size. The donate button is big and red and hard to miss at https://t.co/uolhGspFtN.

If nothing else, please share this, so others can be similarly annoyed with another unsolicited invitation to help us close America's skills gap.

[Lilly Oncology Medical @LillyOncMed]

UPDATED: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer.

Click the image to visit the NCCN website���

Guidelines >Tx by Cancer type > Breast Cancer

[Lilly Oncology Medical @LillyOncMed]

KRAS G12C is distinct from other oncogenic drivers, meaning patients with KRAS G12C–mutant NSCLC need a different approach.

Explore more about this unique disease profile on our website.

[Lilly Oncology Medical @LillyOncMed]

🗣️ Join us for updated efficacy results from the Ph 3 EMBER-3 trial: Use of an oral SERD w/ or w/o a CDK4/6i in patients with ABC. SABCS 2025 | Click to learn more about what we’ll discuss.

[Lilly Oncology Medical @LillyOncMed]

ASH2025 Poster | Learn about on non-covalent BTKi efficacy in treatment-naïve CLL: Bayesian meta-analysis results.

⬇️Click to learn more

[Lilly Oncology Medical @LillyOncMed]

First results from a Phase III study: Non-covalent BTKi vs BR in untreated CLL/SLL patients.

⬇️Click to learn more

ASH2025

[Lilly Oncology Medical @LillyOncMed]

See the results from TRADE | A phase 2 study in early-stage HR+, HER2- breast cancer designed to evaluate if dose escalation of a CDK 4/6 inhibitor would improve tolerability & help patients reach target dose.

🩺 Click below to access the full publication.

[Inluriyo™ (imlunestrant) HCP @InluriyoHCP]

Curious to learn more about Inluriyo’s FDA Approval? Come visit us at Booth 608!

[Lilly Oncology Medical @LillyOncMed]

Learn about SUNRAY-02, a Ph3 trial investigating the addition of a KRASG12C inhibitor to immunotherapy for participants with resected or unresectable KRAS G12C- mutant NSCLC. 🧬

NOW ENROLLING | Click below to find detailed trial & enrollment information.

[Lilly Oncology Medical @LillyOncMed]

🩺 Out now in @Annals_Oncology | Primary overall survival analysis from the monarchE study, evaluating the addition of a CDK 4/6i to ET in HR+, HER2-, high-risk early breast cancer.

Click below to access the full publication.

[Lilly Oncology Medical @LillyOncMed]

NOW PUBLISHED in @Cancers_MDPI:​

Read a real-world study investigating which treatment sequences were associated with better overall survival among CLL patients who had received at least two lines of therapy.​

👇 Click below to see the full analysis.

[Lilly Oncology Medical @LillyOncMed]

🔬Oral presentation | WCLC 2025:

Efficacy and safety results from the LOXO-RAS-20001 and SUNRAY-01 trials, investigating 1L treatment with a KRAS G12C inhibitor + chemoimmunotherapy in KRAS G12C-mutant non-small cell lung cancer (NSCLC).

Click the link below to learn more.

[Bob Whitehead @BobWhitehead12]

@TheJordanRachel 🙏

[Bob Whitehead @BobWhitehead12]

Check out this post on Nextdoor: https://t.co/uwW4ghTc7m

[Terrence K. Williams @w_terrence]

The FBI has released photos of the Person of Interest in the killing of Charlie Kirk

Please take 1 second to help spread this so we can get justice for Charlie Kirk

Anyone who has tips should call the FBI

[Bob Whitehead @BobWhitehead12]

@thomas_garrard Stay strong brother 🙏🙏🙏

[Bishop Robert Barron @BishopBarron]

I am devastated by the news of Charlie Kirk’s death. My prayers go out from the depths of my heart to his family, especially his beloved wife and children. May Christ our Savior welcome Charlie into his heavenly kingdom and may the Lord in his mercy be our consolation and our strength.

[Bob Whitehead @BobWhitehead12]

@glennbeck 🙏🙏🙏🙏